

Subcommittee on Veterinary Antimicrobial Susceptibility Testing – Disclosure of Interests Summary

Personal, Professional, and Financial Interests

Relevant to the field(s) of work in which I would be involved with CLSI, I list below the organizations and activities with which I participate. For example, please list any controlling financial interest or benefit you may hold or have received including consulting fees or paid advisory boards, equity ownership/stock options or other information which your colleagues would need to know in order to fairly assess the basis of your position related to the CLSI activities from past 3 years.

Name Affiliation	Committee Position	Disclosed Financial Interests or Benefits
<p>Mark G. Papich, DVM, MS North Carolina State University</p>	<p>Chairholder</p>	<p>Consultantships - I have been a consultant for the following companies:</p> <ul style="list-style-type: none"> • Zoetis (formerly Pfizer Animal Health) • Bayer Corporation • Merck (MSD Intervet) • Putney Inc., Portland Maine • Novartis Animal Health (now Elanco) • Pennfield Oil (now sold to Phargate) • Akron Molecules (Austria) • Kindred Biosciences Inc. (Kindred Bio), Burlingame, CA • e5pharma, LLC, Ft. Lauderdale, FL <p>Funding Sources - Work in my laboratory has been funded by the following companies or organizations:</p> <ul style="list-style-type: none"> • Bayer Corporation • Zoetis (formerly Pfizer Animal Health) • Morris Animal Foundation • Grayson Jockey Club • Merck • Da Volterra (France) <p>Speaking - The following companies have sponsored some of my speaking activities:</p> <ul style="list-style-type: none"> • Zoetis (formerly Pfizer Animal Health) • Bayer Corporation • Putney Inc. <p>Royalties: I am an author or editor of the following books for which I receive a royalty:</p> <ul style="list-style-type: none"> • Handbook of Veterinary Drugs, 4th edition, published by Elsevier • Veterinary Pharmacology and Therapeutics, 9th and 10th Edition, published by Wiley-Blackwell
<p>Shabbir A. Simjee, PhD Elanco Animal Health</p>	<p>Vice Chairholder</p>	<p>Lilly stock and employed by Elanco Animal Health, a division of Eli Lilly and Company.</p>

Subcommittee on Veterinary Antimicrobial Susceptibility Testing – Disclosure of Interests Summary

Personal, Professional, and Financial Interests

Relevant to the field(s) of work in which I would be involved with CLSI, I list below the organizations and activities with which I participate. For example, please list any controlling financial interest or benefit you may hold or have received including consulting fees or paid advisory boards, equity ownership/stock options or other information which your colleagues would need to know in order to fairly assess the basis of your position related to the CLSI activities from past 3 years.

Name Affiliation	Committee Position	Disclosed Financial Interests or Benefits
Mike Apley, DVM, PhD Kansas State University	Member	Consulting or advisory: <ul style="list-style-type: none"> • National Pork Producers Council • Zoetis Animal Health • Bayer Animal Health • JBS USA • Maple Leaf Foods • National Cattlemen’s Beef Association • Pennfield Animal Health • Boehringer Ingelheim Speaking engagements/presentations (topics centered on the use of drugs in food animals) <ul style="list-style-type: none"> • Veterinary continuing education meetings (198) • Food animal producer meetings (59)
Dubraska V. Diaz-Campos, DVM, PhD Washington State University	Member	None
Cynthia C. Knapp, MS ThermoFisher Scientific	Member	Employee of ThermoFisher Scientific
Brian V. Lubbers, DVM, PhD, DACVCP Kansas State Veterinary Diagnostic Laboratory	Member	Director of Microbial Surveillance Laboratory – a section of KSVDL sponsored by Merck Animal Health
Marilyn N. Martinez, PhD FDA Center for Veterinary Medicine	Member	None

Subcommittee on Veterinary Antimicrobial Susceptibility Testing – Disclosure of Interests Summary

Personal, Professional, and Financial Interests

Relevant to the field(s) of work in which I would be involved with CLSI, I list below the organizations and activities with which I participate. For example, please list any controlling financial interest or benefit you may hold or have received including consulting fees or paid advisory boards, equity ownership/stock options or other information which your colleagues would need to know in order to fairly assess the basis of your position related to the CLSI activities from past 3 years.

Name Affiliation	Committee Position	Disclosed Financial Interests or Benefits
Markus Rose, DVM MSD Animal Health Innovation GmbH, a member of the Merck Animal Health Group	Member	Employee of MSD Animal Health Innovation GmbH, Schwabenheim (Germany), a member of the Merck Animal Health Group
Stefan Schwarz, DVM Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut	Member	Research Grants from the German Research Foundation (DFG) Research Grants from the Federal Ministry of Education and Research (BMBF) Research Grants from the Federal Ministry of Food and Agriculture (BMEL) Financial support for joint research projects from industry partners (Zoetis, Bayer Animal Health) Speaker at meetings organized by bioMérieux, Asklepios, DVG e.V., BpT, BbT, ASM
Thomas R. Shryock, PhD	Member	Owner of shares of Eli Lilly & Co. stock. Managing Member of Antimicrobial Consultants, LLC, which has provided services to HealthForAnimals, Zoetis, and APEX.
Peter Silley, PhD MB Consult Limited	Member	Advisor/Consultant to: Advanced Veterinary Therapeutics, Bayer Animal Health, Boehringer Ingelheim, Cyton Biosciences, Ecosyl, Elanco, Fatro, Huevepharma, IFAH, Kimberly Clark, Lawrence plc, Merck, Merial, Pen & Tec, Phibro, Vetoquinol, Virbac, Zoetis. Employee of MB Consult Limited
Maria M. Traczewski, BS, MT(ASCP) The Clinical Microbiology Institute	Member	CMI has done business or is doing business with the following pharmaceutical companies: AstraZeneca, Cubist, GlaxoSmithKline, Pfizer, Pfizer Animal Health, Bayer, Merck, Astellas, Theravance, Novartis, Paratek, Merck Animal Health, Elanco, Cardeas, BioMerieux, Gilead, Intervet, Vertex, Cornerstone Therapeutics, Cerexa, Shering-Plough Vet. Division, MAP, APP, Novoxel, Protez, Leo, Oscient, Achaogen, Trius, Replidyne, Bausch and Lomb, Blanca, Johnson & Johnson, Wyeth and Sanofi-Aventis, Dechra Pharmaceuticals, APP Pharmaceuticals, Symbiomix Therapeutics, Cepheid Inc., Beckman Coulter-Microscan, Advanced Food Technologies, Stanford University, Zoetis, Inc., and Becton-Dickinson Company
John D. Turnidge, MD Australian Commission for Safety and Quality in Health Care	Member	Advisory boards for Novartis Australia, Pfizer Australia, and AstraZeneca Australia Visiting speaker for bioMerieux
Donald J. Bade Microbial Research, Inc.	Advisor	Owner of a contract research organization that routinely conducts susceptibility testing on a contract basis for veterinary pharmaceutical companies

Subcommittee on Veterinary Antimicrobial Susceptibility Testing – Disclosure of Interests Summary

Personal, Professional, and Financial Interests

Relevant to the field(s) of work in which I would be involved with CLSI, I list below the organizations and activities with which I participate. For example, please list any controlling financial interest or benefit you may hold or have received including consulting fees or paid advisory boards, equity ownership/stock options or other information which your colleagues would need to know in order to fairly assess the basis of your position related to the CLSI activities from past 3 years.

Name Affiliation	Committee Position	Disclosed Financial Interests or Benefits
Steven D. Brown, PhD The Clinical Microbiology Institute	Advisor	None
Virginia R. Fajt, DVM, PhD, DACVCP Texas A & M University	Advisor	I have received no direct benefits nor provided any services in the last three years. Animal health products for research projects I have been involved with have been provided by Zoetis and Merial
Mark D. Fielder, PhD Kingston University	Advisor	Travel costs to CLSI meeting paid by The Society for Applied Microbiology
Thomas R. Fritsche, MD, PhD Marshfield Clinic	Advisor	None
Luca Guardabassi, DVM, PhD University of Copenhagen	Advisor	I hereby state that in the past I received research grants from Pfizer Animal Health and Zoetis to carry out collaborative projects in the area of antimicrobial drug discovery. Furthermore, I received consulting fees from Statens Serum Institut Diagnostica for providing expert advice in the development of a veterinary diagnostic product (Flexicult Vet), and serve as a member of the European Veterinary Committee for Antimicrobial Susceptibility Testing (VetCAST)
Joshua Hayes, PhD FDA Center for Veterinary Medicine	Advisor	None
Cory Langston, DVM, PhD	Advisor	None
Xian-Zhi Li, MD, PhD Health Canada Veterinary Drugs Directorate	Advisor	None
Ron A. Miller, PhD FDA Center for Veterinary Medicine	Advisor	None

Subcommittee on Veterinary Antimicrobial Susceptibility Testing – Disclosure of Interests Summary

Personal, Professional, and Financial Interests

Relevant to the field(s) of work in which I would be involved with CLSI, I list below the organizations and activities with which I participate. For example, please list any controlling financial interest or benefit you may hold or have received including consulting fees or paid advisory boards, equity ownership/stock options or other information which your colleagues would need to know in order to fairly assess the basis of your position related to the CLSI activities from past 3 years.

Name Affiliation	Committee Position	Disclosed Financial Interests or Benefits
Ian Morrissey, B.Sc., MBA, PhD, FRSM IHMA Europe Sàrl, a wholly owned subsidiary of IHMA Inc.	Advisor	None apart from IHMA Europe salary
Dee Shortridge, PhD bioMerieux, Inc.	Advisor	Employee of bioMerieux, Inc.
Virginia B. Sinnott, DVM Angell Animal Medical Center	Advisor	None
Michael T. Sweeney, MS Zoetis, Inc.	Advisor	Employee of Zoetis, Inc.; shareholder in Zoetis stock
Darren Trott The University of Adelaide	Advisor	Research funding in 2014 for Australia-wide antimicrobial resistance surveillance from Zoetis, Inc. Research funding in 2013 (3 years) for multidrug-resistant zoonotic pathogens residing in Australian animals from ARC Linkage (Zoetis, Luoda Pharma, NSW DPI, QDAFF, DAFWA). NHMRC Project grant funding for a new source of antibiotics in 2014. Contract research funding for report on antimicrobial use and antimicrobial resistance in animals in Australia in 2014 from DAFF.
Robert D. Walker, PhD Anti-infectives Research Consultants, LLC	Advisor	None